1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,000 | 0,001 | 08.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.11. | The observation status for QUIA PHARMA AB (publ) is updated | 93 | GlobeNewswire | On June 12, 2025, the shares in QUIA PHARMA AB (the "Company") were given observation status with reference to material adverse uncertainty in respect of the issuer's financial position.
The... ► Artikel lesen | |
| 17.11. | Delisting of QUIA PHARMA AB (publ) from Nasdaq First North Growth Market | 141 | GlobeNewswire | According to item 2.3.7 of the Nasdaq First North Growth Market Rulebook, an issuer shall be able to demonstrate ongoing business operations.
According to item 1.4.2 of the Nasdaq First North... ► Artikel lesen | |
| 12.06. | QUIA PHARMA AB (publ) receives observation status | 285 | GlobeNewswire | On June 5, 2025, QUIA PHARMA AB (publ) (the "Company") disclosed its annual financial report for 2024 with information on the Company's financial situation.
The rules of Nasdaq First North... ► Artikel lesen | |
| QUIA PHARMA Aktie jetzt für 0€ handeln | |||||
| 04.04. | Decision by the Disciplinary Committee regarding QUIA PHARMA AB (publ) | 448 | GlobeNewswire | Stockholm, April 4, 2025- The Disciplinary Committee of Nasdaq Stockholm (the "Exchange") has found that QUIA PHARMA AB (publ) (the "Company") has breached the rules of Nasdaq First North Growth... ► Artikel lesen | |
| 17.02. | XFRA CAPITAL ADJUSTMENT INFORMATION - 17.02.2025 | 1.433 | Xetra Newsboard | Das Instrument 99B0 SE0020678159 QUIA PHARMA AB O.N. EQUITY wird cum Kapitalmassnahme gehandelt am 17.02.2025 und ex Kapitalmassnahme am 18.02.2025 The instrument 99B0 SE0020678159 QUIA PHARMA AB O.N.... ► Artikel lesen | |
| 23.01. | Nasdaq Stockholm AB: QUIA PHARMA AB (publ) receives observation status | 375 | GlobeNewswire | On November 25, 2024, QUIA PHARMA AB (publ) (the "Company") disclosed a press release with information that the Company had received a Statement of Reprimand from Nasdaq Stockholm AB expressing the... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRUCTURE THERAPEUTICS | 70,00 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron | Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 94,30 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis | KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation... ► Artikel lesen | |
| ARCELLX | 74,08 | +6,50 % | Arcellx-Aktie auf Höhenflug nach positiven Daten zu Myelom-Therapie | ||
| PRAXIS PRECISION MEDICINES | 271,33 | 0,00 % | Morning Market Movers: SMX, Praxis Precision Medicines, Polyrizon, Rubrik, Inc. See Big Swings | HONG KONG (dpa-AFX) - At 7:50 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| NURIX THERAPEUTICS | 21,470 | +18,62 % | Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent? | ||
| FULCRUM THERAPEUTICS | 13,000 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting | ? Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at... ► Artikel lesen | |
| DYNE THERAPEUTICS | 22,190 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) | - Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p - Functional improvement... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,25 | -0,53 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| COGENT BIOSCIENCES | 40,350 | +4,08 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| VERA THERAPEUTICS | 45,030 | +0,29 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| TARSUS PHARMACEUTICALS | 82,23 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,830 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| QIAGEN | 39,790 | -1,55 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| DISC MEDICINE | 92,24 | 0,00 % | Disc Medicine stock price target raised to $117 by Raymond James on trial data | ||
| BIONTECH | 83,95 | +0,42 % | Biontech Aktie: CureVac-Fusion vor entscheidender Abstimmung - lohnt sich jetzt das Aktien kaufen? |
QUIA PHARMA AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu QUIA PHARMA AB finden Sie auf Wallstreet Online.